Gyre Therapeutics, Inc. (GYRE) Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. Candel Therapeutics, Inc. (CADL) Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. Jasper Therapeutics, Inc. (JSPR) Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops […]
Read MoreQ32 Bio Inc. is a biotechnology company focused on developing therapies to treat severe autoimmune and inflammatory diseases. The company leverages its deep understanding of immune system biology to create novel treatments that address the underlying causes of these debilitating conditions. Q32 Bio’s pipeline includes both antibody-based therapies and targeted cytokine inhibitors, designed to modulate […]
Read MoreHUTCHMED (China) Limited (HCM) HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. Repligen Corporation (RGEN) Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. […]
Read MoreHumacyte, Inc. is a biotechnology company at the forefront of developing bioengineered human tissues and organs. The company’s proprietary technology platform focuses on creating off-the-shelf, bioengineered human tissues that can be used in a variety of medical applications, including vascular surgeries, kidney dialysis, and other conditions requiring tissue replacement. Humacyte’s key product candidate, the Human […]
Read MoreCorbus Pharmaceuticals Holdings, Inc. (CRBP) is a biopharmaceutical company focused on developing innovative therapies to address rare, chronic, and serious inflammatory and fibrotic diseases. Their main objective is to improve the lives of patients suffering from these debilitating conditions. The company’s key product, lenabasum, is an investigational drug designed to modulate the immune response, reducing […]
Read MoreHumacyte, Inc. (HUMA) Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. Nkarta, Inc. (NKTX) Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. […]
Read MoreAvidity Biosciences, Inc. (RNA) Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. Jumia Technologies AG (JMIA) Jumia Technologies AG operates an e-commerce platform in West Africa, North Africa, East and South Africa, Europe, the United […]
Read MoreCorbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of rare, chronic, and serious inflammatory and fibrotic diseases. Their leading product candidates include anti-inflammatory and anti-fibrotic therapies that target the endocannabinoid system, aiming to provide significant therapeutic benefits for patients with limited treatment […]
Read MoreHumacyte, Inc. is a biotechnology company focused on developing and commercializing bioengineered human tissues and organs. Their primary product, the Human Acellular Vessel (HAV), is designed to address the unmet needs in vascular surgery and hemodialysis access. These bioengineered vessels aim to improve patient outcomes by offering a reliable and durable alternative to synthetic and […]
Read MoreLENZ Therapeutics, Inc. (LENZ) LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Applied Therapeutics, Inc. (APLT) Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in […]
Read MoreJanux Therapeutics Inc. JANX is a biotechnology company specializing in the development of novel cancer immunotherapies designed to enhance the body’s ability to harness the immune system to combat cancer. The company focuses on creating therapies that are not only effective but also have reduced side effects, improving patient outcomes in the fight against cancer. […]
Read MoreVera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is […]
Read MoreJasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique […]
Read MoreMarket conditions are Bullish in a Bull Market as of 2024-03-27. This means traders and investors should consider trading with a Bullish bias by buying (going long) stocks, long ETF’s or Call Options. The rank of the Bull Market is 21.62 which indicates the current market conditions are Extreme, Risk of a reversal is high. […]
Read MoreMarket conditions are Bullish in a Bull Market as of 2024-03-26. This means traders and investors should consider trading with a Bullish bias by buying (going long) stocks, long ETF’s or Call Options. The rank of the Bull Market is 21.46 which indicates the current market conditions are Extreme, Risk of a reversal is high. […]
Read More